Nisa Investment Advisors
ADCT icon

Nisa Investment Advisors’s ADC Therapeutics ADCT Stock Holding History

Nisa Investment Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39K Hold
370
– – ﹤0.01% 2682
2025
Q4 		$1.31K Hold
370
– – ﹤0.01% 2673
2025
Q3 		$1.48K Sell
370
-59
-14% -$186 ﹤0.01% 2675
2025
Q2 		$1.15K Sell
429
-5,317
-93% -$11.2K ﹤0.01% 2708
2025
Q1 		$8.1K Buy
5,746
+5,561
+3,006% +$9.45K ﹤0.01% 2148
2024
Q4 		$368 Buy
185
+70
+61% +$183 ﹤0.01% 2877
2024
Q3 		$362 Buy
+115
New +$363 ﹤0.01% 2775

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nisa Investment Advisors's ADCT Position: Q1 2026 in Review

Nisa Investment Advisors held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 370 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2682.

Nisa Investment Advisors first reported a position in ADCT in Q3 2024 and has held it in 7 quarters since. The position peaked at $8.1K in Q1 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Nisa Investment Advisors held 370 shares of ADC Therapeutics worth $1.39K as of Q1 2026.
  • Nisa Investment Advisors left its ADC Therapeutics share count unchanged in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2682 holding.
  • Nisa Investment Advisors first reported a position in ADC Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Nisa Investment Advisors's ADC Therapeutics position peaked at $8.1K in Q1 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.